NASDAQ:XOMA XOMA (XOMA) Stock Price, News & Analysis $27.28 +0.66 (+2.48%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$26.16▼$28.0650-Day Range$23.10▼$29.5052-Week Range$13.48▼$30.36Volume30,223 shsAverage Volume20,773 shsMarket Capitalization$317.51 millionP/E RatioN/ADividend YieldN/APrice Target$78.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get XOMA alerts: Email Address XOMA MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside187.8% Upside$78.50 Price TargetShort InterestBearish2.23% of Shares Sold ShortDividend StrengthN/ASustainability-0.22Upright™ Environmental ScoreNews Sentiment0.15Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.42) to ($0.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.48 out of 5 starsMedical Sector255th out of 910 stocksPharmaceutical Preparations Industry107th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingXOMA has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageXOMA has only been the subject of 1 research reports in the past 90 days.Read more about XOMA's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.23% of the outstanding shares of XOMA have been sold short.Short Interest Ratio / Days to CoverXOMA has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.Change versus previous monthShort interest in XOMA has recently decreased by 3.64%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldXOMA does not currently pay a dividend.Dividend GrowthXOMA does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXOMA has received a 26.63% net impact score from Upright. The largest positive contribution comes from its "Distributing knowledge" impact, which is false driven by its "Mutual funds investing in the pharmaceuticals industry" product. See details.Environmental SustainabilityThe Environmental Impact score for XOMA is -0.22. Previous Next 1.7 News and Social Media Coverage News SentimentXOMA has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for XOMA this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, XOMA insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.20% of the stock of XOMA is held by insiders.Percentage Held by Institutions95.92% of the stock of XOMA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about XOMA's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for XOMA are expected to grow in the coming year, from ($1.42) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of XOMA is -6.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XOMA is -6.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXOMA has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about XOMA's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm Press Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.Full details are in this announcement. About XOMA Stock (NASDAQ:XOMA)XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.Read More XOMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XOMA Stock News HeadlinesSeptember 5 at 9:12 AM | wsj.comXOMA Royalty Corp. 8.625% Pfd. Series ASeptember 4 at 7:30 AM | globenewswire.comXOMA Royalty to Present at Upcoming Investor Conferences in SeptemberSeptember 7, 2024 | Porter & Company (Ad)The death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.August 16, 2024 | markets.businessinsider.comRisinger Affirms Buy Rating on Xoma with Increased Price Target Amid Strong Financial Performance and Unrecognized Asset PotentialAugust 13, 2024 | investorplace.comXOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024August 13, 2024 | globenewswire.comXOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent ActivitiesAugust 3, 2024 | finance.yahoo.comBMRN Aug 2024 115.000 call (BMRN240816C00115000)July 25, 2024 | finance.yahoo.comU.S. Biodefense Industry Research 2024-2030: Focus on Anthrax, Small Pox, Botulism, & Radiation/NuclearSeptember 7, 2024 | Porter & Company (Ad)The death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.July 22, 2024 | finance.yahoo.comLatigo Biotherapeutics Appoints Nima Farzan as Chief Executive Officer, Positioning Company for Rapid GrowthJune 29, 2024 | seekingalpha.comXOMA Corporation: A Hold Rating With Steady Income From Preferred SharesJune 20, 2024 | globenewswire.comXOMA Declares Quarterly Preferred Stock DividendsJune 12, 2024 | globenewswire.comXOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review VoucherJune 12, 2024 | investorplace.com3 Crazy Good Stocks to Buy With $500 Right NowJune 3, 2024 | businesswire.comLadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin LicenseMay 14, 2024 | globenewswire.comXOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQMay 9, 2024 | investorplace.comXOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | globenewswire.comXOMA Reports First Quarter 2024 Financial Results and Highlights Recent ActivitiesSee More Headlines Receive XOMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:XOMA CUSIP98419J10 CIK791908 Webwww.xoma.com Phone(510) 204-7200Fax510-649-7571Employees10Year Founded1981Price Target and Rating Average Stock Price Target$78.50 High Stock Price Target$117.00 Low Stock Price Target$40.00 Potential Upside/Downside+187.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,830,000.00 Net Margins-128.59% Pretax Margin-119.61% Return on Equity-24.50% Return on Assets-11.24% Debt Debt-to-Equity Ratio1.15 Current Ratio8.71 Quick Ratio8.71 Sales & Book Value Annual Sales$9.81 million Price / Sales32.38 Cash FlowN/A Price / Cash FlowN/A Book Value$8.54 per share Price / Book3.19Miscellaneous Outstanding Shares11,639,000Free Float10,801,000Market Cap$317.51 million OptionableOptionable Beta0.93 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Owen P. Hughes Jr. (Age 49)CEO & Director Comp: $193.75kMr. Thomas M. Burns (Age 50)Senior VP of Finance & CFO Comp: $759.24kMr. Brad Sitko (Age 43)Chief Investment Officer Comp: $867.08kKey CompetitorsProgenics PharmaceuticalsNASDAQ:PGNXOsmotica PharmaceuticalsNASDAQ:OSMTSyros PharmaceuticalsNASDAQ:SYRSCue BiopharmaNASDAQ:CUETherapeuticsMDNASDAQ:TXMDView All CompetitorsInsiders & InstitutionsStonepine Capital Management LLCSold 3,641 shares on 8/21/2024Ownership: 2.138%Dimensional Fund Advisors LPSold 3,102 shares on 8/9/2024Ownership: 0.193%Rhumbline AdvisersBought 1,334 shares on 8/1/2024Ownership: 0.083%Bank of New York Mellon CorpBought 1,968 shares on 7/26/2024Ownership: 0.538%Bradley SitkoBought 1,500 shares on 10/2/2023Total: $21,375.00 ($14.25/share)View All Insider TransactionsView All Institutional Transactions XOMA Stock Analysis - Frequently Asked Questions How have XOMA shares performed this year? XOMA's stock was trading at $18.50 at the start of the year. Since then, XOMA stock has increased by 47.5% and is now trading at $27.28. View the best growth stocks for 2024 here. How were XOMA's earnings last quarter? XOMA Co. (NASDAQ:XOMA) issued its quarterly earnings results on Tuesday, August, 13th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02. The biotechnology company had revenue of $11.09 million for the quarter, compared to the consensus estimate of $8.37 million. XOMA had a negative trailing twelve-month return on equity of 24.50% and a negative net margin of 128.59%. What is John Varian's approval rating as XOMA's CEO? 11 employees have rated XOMA Chief Executive Officer John Varian on Glassdoor.com. John Varian has an approval rating of 73% among the company's employees. Who are XOMA's major shareholders? Top institutional shareholders of XOMA include Stonepine Capital Management LLC (2.14%), Bank of New York Mellon Corp (0.54%), Dimensional Fund Advisors LP (0.19%) and Rhumbline Advisers (0.08%). Insiders that own company stock include Bvf Partners L P/Il, James R Neal, Thomas M Burns, Bradley Sitko and Owen Hughes. View institutional ownership trends. How do I buy shares of XOMA? Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of XOMA own? Based on aggregate information from My MarketBeat watchlists, some other companies that XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), OPKO Health (OPK) and Uranium Energy (UEC). This page (NASDAQ:XOMA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
